Rigel Pharmaceuticals (RIGL) 2.47 $RIGL
CGEN, RIGL, SPRT, AMRN, STON, PFH Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Feb 02, 4:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Compugen Ltd (NASDAQ:CGEN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Support.com Inc (NASDAQ:SPRT), Amarin Corp PLC (NASDAQ:AMRN), Stonemor Partners L.P. (NASDAQ:STON), Corporate Asset Backed Corp (NYSE
FH) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
STON: 28.02 (-0.32), AMRN: 1.18 (unch), SPRT: 1.78 (+0.04), CGEN: 8.19 (+0.08), PFH: 18.56 (+0.36), RIGL: 2.47 (+0.05)
Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Thu Jan 08, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present updated product development plans and a financial update at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15th at 9:00 a.m. PT (see webcast details below).
JPM: 59.67 (+0.10), RIGL: 2.47 (+0.05)
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
GlobeNewswire - Mon Jan 05, 3:39PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
KYTH: 39.72 (+0.62), RIGL: 2.47 (+0.05)
Hot Stock: Rigel Pharmaceuticals, Shares Gain 5.5% (RIGL)
Comtex SmarTrend(R) - Fri Dec 19, 12:40PM CST
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 5.5% to $2.48 on 1.2x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 560,000 shares, vs. average volume of 466,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's 0.0%) and outperformed the S&P 500 (5.5% to the S&P's 0.2%) during today's trading.
RIGL: 2.47 (+0.05)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jbcb9/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Boehringer Ingelheim - Amgen - GlaxoSmithKline - Merck & Co - Symphogen - Eisai - Rigel Pharmaceuticals - Immunomedics - HanAll Biopharma - PhytoHealth - Anthera Pharmaceuticals - SuppreMol - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/3jbcb9/idiopathic
IMMU: 3.84 (unch), ANTH: 3.84 (+0.06), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), RIGL: 2.47 (+0.05)
Is Rigel Pharmaceuticals (RIGL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 7:49AM CST
Rigel Pharmaceuticals is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
RIGL: 2.47 (+0.05)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Intermittent Claudication - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/59bmx9/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2013" report to their offering. 'Intermittent Claudication - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intermittent Claudication. Intermittent Claudication - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Nissan Chemical Industries, Ltd. - Sangamo BioSciences, Inc. - Rigel Pharmaceuticals, Inc. - Sigma-Tau S.p.A. - Cytokinetics, Incorporated - Cytomedix, Inc. - Pluristem Therapeutics Inc. - LTT Bio-Pharma Co., Ltd. - Taisho Toyama Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/59...termittent
CYTK: 7.78 (+1.29), PSTI: 2.91 (+0.01), SGMO: 15.40 (+0.14), RIGL: 2.47 (+0.05)
Rigel Announces Executive Management Changes
PR Newswire - Mon Nov 24, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as the company's president and chief operating officer, will assume the position of chief executive officer and join the board of directors. Gary Lyons, a member of Rigel's Board of Directors since 2005, will become chairman. Mr. Gower is expected to remain an employee until the end of the year and, thereafter will be a consultant to the company providing advice on strategy, business development and other matters.
RIGL: 2.47 (+0.05)
Rigel posts 3Q loss
Automated Insights - Tue Nov 04, 8:37AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $20.9 million, or 24 cents per share, in its third quarter.
RIGL: 2.47 (+0.05)
Rigel Pharmaceuticals beats by $0.03
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:40AM CST
RIGL: 2.47 (+0.05)
Rigel Announces Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 04, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2014.
RIGL: 2.47 (+0.05)
Rigel's R348 Fails in Phase II Study, Shares Down 13.6% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 2:30PM CDT
Rigel Pharmaceuticals, Inc. (RIGL) R348 failed to meet the primary and secondary endpoints in a phase II study for the treatment of dry eye disease.
ENDP: 84.01 (+1.12), UTHR: 151.11 (+3.59), ANAC: 40.76 (-0.07), RIGL: 2.47 (+0.05)
Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today
at The Street - Wed Aug 13, 2:37PM CDT
Rigel Pharmaceuticals (RIGL) shares are down after the company announced that it was stopping the testing of its dry eye disease treatment.
RIGL: 2.47 (+0.05)
Investors look to Lighten Up on Shares of Rigel Pharmaceuticals, Shares Down 10.0% (RIGL)
Comtex SmarTrend(R) - Wed Aug 13, 10:33AM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's worst performing low-priced stocks, down 10.0% to $2.78 on 2.2x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 875,000 shares, vs. average volume of 390,000 shares per day. The stock has underperformed the Dow (-10.0% to the Dow's 0.3%) and underperformed the S&P 500 (-10.0% to the S&P's 0.4%) during today's trading.
RIGL: 2.47 (+0.05)
R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
PR Newswire - Wed Aug 13, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo. No significant adverse events were reported in the trial. Rigel has decided not to initiate any new studies of R348 for this indication, but is continuing its Phase 2 study of dry eye in patients with graft versus host disease (GvHD).
RIGL: 2.47 (+0.05)
Rigel Pharmaceuticals Down 7.5%, Shares Slide into the Red (RIGL)
Comtex SmarTrend(R) - Tue Aug 05, 12:43PM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's worst performing low-priced stocks, down 7.5% to $3.14 on 1.1x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 461,000 shares, vs. average volume of 408,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.9%) and underperformed the S&P 500 (-7.5% to the S&P's -1.0%) during today's trading.
RIGL: 2.47 (+0.05)
Rigel Announces Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 05, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014.
RIGL: 2.47 (+0.05)
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), RIGL: 2.47 (+0.05), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
CGEN, RIGL, SPRT, AMRN, STON, PFH Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Feb 02, 4:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Compugen Ltd (NASDAQ:CGEN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Support.com Inc (NASDAQ:SPRT), Amarin Corp PLC (NASDAQ:AMRN), Stonemor Partners L.P. (NASDAQ:STON), Corporate Asset Backed Corp (NYSE
FH) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: STON: 28.02 (-0.32), AMRN: 1.18 (unch), SPRT: 1.78 (+0.04), CGEN: 8.19 (+0.08), PFH: 18.56 (+0.36), RIGL: 2.47 (+0.05)
Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Thu Jan 08, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present updated product development plans and a financial update at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15th at 9:00 a.m. PT (see webcast details below).
JPM: 59.67 (+0.10), RIGL: 2.47 (+0.05)
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
GlobeNewswire - Mon Jan 05, 3:39PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
KYTH: 39.72 (+0.62), RIGL: 2.47 (+0.05)
Hot Stock: Rigel Pharmaceuticals, Shares Gain 5.5% (RIGL)
Comtex SmarTrend(R) - Fri Dec 19, 12:40PM CST
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 5.5% to $2.48 on 1.2x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 560,000 shares, vs. average volume of 466,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's 0.0%) and outperformed the S&P 500 (5.5% to the S&P's 0.2%) during today's trading.
RIGL: 2.47 (+0.05)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jbcb9/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Boehringer Ingelheim - Amgen - GlaxoSmithKline - Merck & Co - Symphogen - Eisai - Rigel Pharmaceuticals - Immunomedics - HanAll Biopharma - PhytoHealth - Anthera Pharmaceuticals - SuppreMol - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/3jbcb9/idiopathic
IMMU: 3.84 (unch), ANTH: 3.84 (+0.06), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), RIGL: 2.47 (+0.05)
Is Rigel Pharmaceuticals (RIGL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 7:49AM CST
Rigel Pharmaceuticals is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
RIGL: 2.47 (+0.05)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Intermittent Claudication - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/59bmx9/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2013" report to their offering. 'Intermittent Claudication - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intermittent Claudication. Intermittent Claudication - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Nissan Chemical Industries, Ltd. - Sangamo BioSciences, Inc. - Rigel Pharmaceuticals, Inc. - Sigma-Tau S.p.A. - Cytokinetics, Incorporated - Cytomedix, Inc. - Pluristem Therapeutics Inc. - LTT Bio-Pharma Co., Ltd. - Taisho Toyama Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/59...termittent
CYTK: 7.78 (+1.29), PSTI: 2.91 (+0.01), SGMO: 15.40 (+0.14), RIGL: 2.47 (+0.05)
Rigel Announces Executive Management Changes
PR Newswire - Mon Nov 24, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as the company's president and chief operating officer, will assume the position of chief executive officer and join the board of directors. Gary Lyons, a member of Rigel's Board of Directors since 2005, will become chairman. Mr. Gower is expected to remain an employee until the end of the year and, thereafter will be a consultant to the company providing advice on strategy, business development and other matters.
RIGL: 2.47 (+0.05)
Rigel posts 3Q loss
Automated Insights - Tue Nov 04, 8:37AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $20.9 million, or 24 cents per share, in its third quarter.
RIGL: 2.47 (+0.05)
Rigel Pharmaceuticals beats by $0.03
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:40AM CST
RIGL: 2.47 (+0.05)
Rigel Announces Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 04, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2014.
RIGL: 2.47 (+0.05)
Rigel's R348 Fails in Phase II Study, Shares Down 13.6% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 2:30PM CDT
Rigel Pharmaceuticals, Inc. (RIGL) R348 failed to meet the primary and secondary endpoints in a phase II study for the treatment of dry eye disease.
ENDP: 84.01 (+1.12), UTHR: 151.11 (+3.59), ANAC: 40.76 (-0.07), RIGL: 2.47 (+0.05)
Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today
at The Street - Wed Aug 13, 2:37PM CDT
Rigel Pharmaceuticals (RIGL) shares are down after the company announced that it was stopping the testing of its dry eye disease treatment.
RIGL: 2.47 (+0.05)
Investors look to Lighten Up on Shares of Rigel Pharmaceuticals, Shares Down 10.0% (RIGL)
Comtex SmarTrend(R) - Wed Aug 13, 10:33AM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's worst performing low-priced stocks, down 10.0% to $2.78 on 2.2x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 875,000 shares, vs. average volume of 390,000 shares per day. The stock has underperformed the Dow (-10.0% to the Dow's 0.3%) and underperformed the S&P 500 (-10.0% to the S&P's 0.4%) during today's trading.
RIGL: 2.47 (+0.05)
R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
PR Newswire - Wed Aug 13, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo. No significant adverse events were reported in the trial. Rigel has decided not to initiate any new studies of R348 for this indication, but is continuing its Phase 2 study of dry eye in patients with graft versus host disease (GvHD).
RIGL: 2.47 (+0.05)
Rigel Pharmaceuticals Down 7.5%, Shares Slide into the Red (RIGL)
Comtex SmarTrend(R) - Tue Aug 05, 12:43PM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's worst performing low-priced stocks, down 7.5% to $3.14 on 1.1x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 461,000 shares, vs. average volume of 408,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.9%) and underperformed the S&P 500 (-7.5% to the S&P's -1.0%) during today's trading.
RIGL: 2.47 (+0.05)
Rigel Announces Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 05, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014.
RIGL: 2.47 (+0.05)
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), RIGL: 2.47 (+0.05), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
